亿帆医药：在研产品断金戒毒胶囊Ib期临床试验结果达到预期目标

Core Viewpoint - Yifan Pharmaceutical's subsidiary has successfully completed Phase Ib clinical trials for its drug, Duanjin Detoxification Capsule, demonstrating safety, tolerability, and pharmacokinetic characteristics in patients with opioid addiction [1] Group 1: Clinical Trial Results - The Duanjin Detoxification Capsule has shown a significant trend in preventing relapse, improving behavioral control, and enhancing rehabilitation quality compared to a placebo in patients recovering from opioid addiction [1] - The clinical trial results indicate that the drug meets the expected goals for Phase Ib trials in opioid addiction recovery patients [1] Group 2: Company Development - Yifan Pharmaceutical's full subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., is responsible for the development and clinical trials of the Duanjin Detoxification Capsule [1]